Get the Stockscreener App
1,185.87
1.97%
22.86
After Hours:
1185.50
-0.37
-0.03%
Overview
News
Price History
Option Chain
Financials
Why LLY Down?
Discussions
Forecast
Stock Split
Dividend History
Lilly Eli Co stock is traded at $1,185.87, with a volume of 1.91M.
It is up +1.97% in the last 24 hours and up +7.12% over the past month.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
See More
Previous Close:
$1,163.01
Open:
$1146.615
24h Volume:
1.91M
Relative Volume:
0.61
Market Cap:
$1.06T
Revenue:
$72.25B
Net Income/Loss:
$25.28B
P/E Ratio:
42.69
EPS:
27.781
Net Cash Flow:
$10.37B
1W Performance:
+1.43%
1M Performance:
+7.12%
6M Performance:
+11.42%
1Y Performance:
+48.44%
1-Day Range:
$1,141.78
$1,189.59
1-Week Range:
$1,139.00
$1,189.59
52-Week Range:
$623.78
$1,249.45
Lilly Eli Co Stock (LLY) Company Profile
Name
Lilly Eli Co
Sector
Industry
Phone
(317) 276-2000
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY vs JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
1,185.87 | 1.04T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
259.27 | 615.36B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
256.92 | 447.53B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
130.48 | 314.83B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
156.14 | 290.96B | 54.66B | 13.58B | 16.05B | 7.0171 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-17-26 | Downgrade | HSBC Securities | Hold → Reduce |
| Feb-25-26 | Initiated | RBC Capital Mkts | Outperform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-16-25 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-15-25 | Reiterated | BofA Securities | Buy |
| Dec-15-25 | Reiterated | Goldman | Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-10-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-20-25 | Reiterated | BMO Capital Markets | Outperform |
| Oct-14-25 | Upgrade | Erste Group | Hold → Buy |
| Sep-17-25 | Downgrade | Berenberg | Buy → Hold |
| Aug-27-25 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-18-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Aug-07-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-05-25 | Downgrade | Erste Group | Buy → Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Reduce |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Sep-13-24 | Resumed | Citigroup | Buy |
| Aug-12-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-21-24 | Downgrade | DZ Bank | Buy → Hold |
| Feb-16-24 | Reiterated | Morgan Stanley | Overweight |
| Dec-21-23 | Downgrade | Daiwa Securities | Buy → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-20-23 | Resumed | UBS | Buy |
| Aug-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-26-23 | Reiterated | Citigroup | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-24-23 | Reiterated | BofA Securities | Buy |
| May-24-23 | Reiterated | UBS | Buy |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-15-23 | Downgrade | Societe Generale | Hold → Sell |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Sep-22-22 | Upgrade | UBS | Neutral → Buy |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Mar-10-22 | Initiated | Daiwa Securities | Outperform |
| Jan-21-22 | Upgrade | DZ Bank | Hold → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-16-21 | Reiterated | BMO Capital Markets | Outperform |
| Dec-16-21 | Reiterated | BofA Securities | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-11-21 | Upgrade | Berenberg | Hold → Buy |
| Sep-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-05-21 | Upgrade | DZ Bank | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Jun-24-21 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-19-21 | Upgrade | Mizuho | Neutral → Buy |
| Dec-10-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Sep-03-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-21-20 | Downgrade | UBS | Buy → Neutral |
| Apr-09-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Dec-18-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-28-19 | Initiated | Goldman | Buy |
| Apr-24-19 | Upgrade | Edward Jones | Hold → Buy |
| Apr-11-19 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-19 | Initiated | JP Morgan | Overweight |
| Jan-23-19 | Initiated | UBS | Buy |
| Nov-26-18 | Downgrade | Citigroup | Buy → Neutral |
| Oct-31-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Oct-01-18 | Reiterated | SunTrust | Buy |
| Sep-26-18 | Resumed | JP Morgan | Overweight |
View All
Lilly Eli Co Stock (LLY) Latest News
Novo Nordisk’s fight against Eli Lilly has gone legal: A top lawyer evaluates the case - Business Post
Scribe Therapeutics Announces Pricing of Upsized Initial Public Offering - GlobeNewswire Inc.
Eli Lilly Reports Positive Results from Two Phase III Trials | PharmExec - Pharmaceutical Executive
Novo Nordisk Sues Eli Lilly Over Zepbound and Mounjaro Advertising Claims - Law Commentary
Eli Lilly (NYSE:LLY) Shapes the Healthcare Earnings Narrative - Kalkine Media
Lilly, with new data, to seek FDA approval of obesity drug retatrutide - BioPharma Dive
Lilly to file for next-gen obesity drug approval in early 2027 - Yahoo Finance
Eli Lilly (NYSE:LLY) Growth & Technical Setup Signal A Key Market Test - Kalkine Media
Lilly preps FDA run for ‘triple-G’ weight loss drug with Phase 3 data - BioSpace
Lilly Endowment reports 90.4M Eli Lilly (LLY) shares, a 9.6% stake - Stock Titan
How Will Eli Lilly's GLP-1 Portfolio Sales Aid Upcoming Q2 Results? - Yahoo Finance UK
Eli Lilly’s Anticipated Weight Loss Drug Helped People Lose 56 Pounds On Average - Forbes
Eli Lilly Delay Puts Madrigal Stock In Focus For Obesity Drug Investors - simplywall.st
Lilly announces more next-gen obesity drug data, plans Q1 2027 FDA application - Reuters
Eli Lilly (LLY) Advances Next-Gen Weight-Loss Therapy with Promi - GuruFocus
Eli Lilly presents positive safety data but postpones weight-loss candidate application - medwatch.com
Eli Lilly to File FDA Approval for Retatrutide in 2027 After Five Positive Phase 3 Trials - MLQ.ai
Eli Lilly and Co.'s next-generation obesity drug has had its market application delayed until 2027. - 富途牛牛
Eli Lilly (LLY) Reports Positive Phase 3 Trial Results for Retat - GuruFocus
Eli Lilly to seek obesity drug approval in Q1 2027 - Breakingthenews.net
Eli Lilly to seek approval for powerful new obe... - Pluang
Lilly’s retatrutide meets endpoints in two phase 3 obesity trials - Investing.com
New data on Eli Lilly’s ‘triple-G’ drug leave open questions on heart benefit - STAT
Eli Lilly Preparing Retatrutide Applications After Positive Weight-Loss Data - WSJ
Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C - Eli Lilly and Company
Eli Lilly (NYSE:LLY) Shows Strong Growth and Breakout Technical Setup - ChartMill
Novo Nordisk Sues Eli Lilly Over Wegovy and Mounjaro Obesity Drug Ads - 동아사이언스
Watch Lilly’s Next-Generation Obesity Shot Clears Another Hurdle - Bloomberg.com
Whiz Buckley On Eli Lilly’s Psychedelic Takeout - The Dales Report
Novo Nordisk Sues Rival Eli Lilly Over Advertising - WFXB
Form 4 Eli lilly For: 22 July By Investing.com - Investing.com Canada
Novo Nordisk Says Lilly’s ‘Gold Standard’ GLP-1 Comparison Misleads Consumers - Law.com
Historic Indy estate built for Eli Lilly executive hits market for $7.99 million - WISH-TV
The Zacks Analyst Blog Highlights Eli Lilly, Costco Wholesale, Morgan Stanley and Kewaunee Scientific - Yahoo Finance UK
Lilly Confirms Date and Conference Call for Second-quarter 2026 Financial Results Announcement - 富途牛牛
What You Need to Know Ahead of Eli Lilly's Earnings Release - Yahoo Finance
Novo Nordisk launches legal battle against Eli Lilly: Here are the claims - medwatch.com
What we know of weight-loss drugs’ pricing, availability as Novo sues Lilly - Reuters
Novo Nordisk sues Eli Lilly in US over ‘misleading’ obesity drug advertising claims - Irish Independent
$Eli Lilly and Co (LLY.US)$ - Moomoo
Novo Nordisk Takes Rival Eli Lilly to Court Over Weight-Loss Ad Claims - The Daily Upside
Novo Nordisk Sues Eli Lilly Over Misleading GLP-1 Ad Campaigns - scanx.trade
Novo Nordisk Sues Eli Lilly Over ‘Deceptive’ GLP-1 Ads, Stock Impact Seen Limited - NAI500
Rznomics Secures Additional Research Funding from Lilly for Hereditary Deafness Treatment - Seoul Economic Daily
Novo Nordisk sues Eli Lilly, alleges deceptive advertising for Zepbound - WISH-TV
Novo's False Ad Suit Against Eli Lilly Ramps Up GLP-1 Rivalry - Law360
Novo Nordisk Sues Eli Lilly Over Weight-Loss Drug Ads - Briefs Finance
Weight-loss drug maker sues rival over which GLP-1 sheds the most pounds - The Independent
Top Research Reports for Eli Lilly, Costco & Morgan Stanley - Zacks Investment Research
Novo sues Lilly, claiming misleading ads in weight-loss drug battle - Reuters
Novo Nordisk sues Eli Lilly, alleging the company's GLP-1 ads are 'deliberately false' - AOL.com
Lilly Eli Co Stock (LLY) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.42%
0.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):